Skip to main content

Advertisement

SpringerLink
Log in

Research progress on the role of cationic amino acid transporter (CAT) family members in malignant tumors and immune microenvironment

  • Review Article
  • Published:
Amino Acids Aims and scope Submit manuscript

Abstract

Amino acids are essential for the survival of all living organisms and living cells. Amino acid transporters mediate the transport and absorption of amino acids, and the dysfunction of these proteins can induce human diseases. Cationic amino acid transporters (CAT family, SLC7A1-4, and SLC7A14) are considered to be a group of transmembrane transporters, of which SLC7A1-3 are essential for arginine transport in mammals. Numerous studies have shown that CAT family-mediated arginine transport is involved in signal crosstalk between malignant tumor cells and immune cells, especially T cells. The modulation of extracellular arginine concentration has entered a number of clinical trials and achieved certain therapeutic effects. Here, we review the role of CAT family on tumor cells and immune infiltrating cells in malignant tumors and explore the therapeutic strategies to interfere with extracellular arginine concentration, to elaborate its application prospects. CAT family members may be used as biomarkers for certain cancer entities and might be included in new ideas for immunotherapy of malignant tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Data sharing does not apply to this paper, because no corresponding experimental data were generated during the current study. Some of the data supporting the article can be found in the hyperlink to the manuscript.

References

  • Abdelmagid SA, Rickard JA, Mcdonald WJ et al (2011) CAT-1-mediated arginine uptake and regulation of nitric oxide synthases for the survival of human breast cancer cell lines. J Cell Biochem 112(4):1084–1092

    Article  CAS  PubMed  Google Scholar 

  • Abou-Alfa GK, Qin S, Ryoo BY et al (2018) Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol 29(6):1402–1408

    Article  CAS  PubMed  Google Scholar 

  • Agrawal V, Woo JH, Mauldin JP et al (2012) Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells. Anticancer Drugs 23(1):51–64

    Article  CAS  PubMed  Google Scholar 

  • Albritton LM, Tseng L, Scadden D et al (1989) A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell 57(4):659–666

    Article  CAS  PubMed  Google Scholar 

  • Al-Koussa H, Al-Haddad M, Abi-Habib R et al (2019) Human recombinant arginase I [HuArgI (Co)-PEG5000]-induced arginine depletion inhibits colorectal cancer cell migration and invasion. Int J Mol Sci 20(23)

  • Bai L, Sato H, Kubo Y et al (2019) CAT1/SLC7A1 acts as a cellular receptor for bovine leukemia virus infection. FASEB J 33(12):14516–14527

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bian Y, Li W, Kremer DM et al (2020) Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature 585(7824):277–282

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bowles TL, Kim R, Galante J et al (2008) Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 123(8):1950–1955

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brin E, Wu K, Lu HT et al (2017) PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. Oncotarget 8(35):58948–58963

    Article  PubMed  PubMed Central  Google Scholar 

  • Chang KY, Chiang NJ, Wu SY et al (2021) Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. Oncoimmunology 10(1):1943253

    Article  PubMed  PubMed Central  Google Scholar 

  • Chedid V, Vijayvargiya P, Camilleri M (2018) Elobixibat for the treatment of constipation. Expert Rev Gastroenterol Hepatol 12(10):951–960

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen CL, Hsu SC, Ann DK et al (2021) Arginine signaling and cancer metabolism. Cancers 13(14)

  • Cheng PN, Lam TL, Lam WM et al (2007) Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 67(1):309–317

    Article  CAS  PubMed  Google Scholar 

  • Cheon DJ, Walts AE, Beach JA et al (2015) Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. J Pathol Clin Res 1(1):41–53

    Article  CAS  PubMed  Google Scholar 

  • Cimen Bozkus C, Elzey BD, Crist SA et al (2015) Expression of cationic amino acid transporter 2 is required for myeloid-derived suppressor cell-mediated control of T cell immunity. J Immunol 195(11):5237–5250

    Article  CAS  PubMed  Google Scholar 

  • Closs EI, Boissel JP, Habermeier A et al (2006) Structure and function of cationic amino acid transporters (CATs). J Membr Biol 213(2):67–77

    Article  CAS  PubMed  Google Scholar 

  • Closs EI, Simon A, Vékony N et al (2004) Plasma membrane transporters for arginine. J Nutr 134(10 Suppl):2752S-2759S (discussion 65S–67S)

    Article  CAS  PubMed  Google Scholar 

  • Coburn LA, Singh K, Asim M et al (2019) Loss of solute carrier family 7 member 2 exacerbates inflammation-associated colon tumorigenesis. Oncogene 38(7):1067–1079

    Article  CAS  PubMed  Google Scholar 

  • Delage B, Luong P, Maharaj L et al (2012) Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis 3(7):e342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Du F, Zheng F, Han Y et al (2022) Novel immune-related gene signature for risk stratification and prognosis of survival in ER (+) and/or PR (+) and HER2 (-) breast cancer. Front Pharmacol 13:820437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Eckert MA, Coscia F, Chryplewicz A et al (2019) Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature 569(7758):723–728

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • El-Mais N, Fakhoury I, Al Haddad M et al (2021) Human recombinant arginase I [HuArgI(Co)-PEG5000]-induced arginine depletion inhibits pancreatic cancer cell migration and invasion through autophagy. Pancreas 50(8):1187–1194

    Article  CAS  PubMed  Google Scholar 

  • Ensor CM, Holtsberg FW, Bomalaski JS et al (2002) Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62(19):5443–5450

    CAS  PubMed  Google Scholar 

  • Fan A, Zhang Y, Cheng J et al (2022) A novel prognostic model for prostate cancer based on androgen biosynthetic and catabolic pathways. Front Oncol 12:950094

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Feun LG, Marini A, Walker G et al (2012) Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer 106(9):1481–1485

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fotiadis D, Kanai Y, Palacín M (2013) The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med 34(2–3):139–158

    Article  CAS  PubMed  Google Scholar 

  • Fultang L, Vardon A, De Santo C et al (2016) Molecular basis and current strategies of therapeutic arginine depletion for cancer. Int J Cancer 139(3):501–509

    Article  CAS  PubMed  Google Scholar 

  • Garibsingh RA, Schlessinger A (2019) Advances and challenges in rational drug design for SLCs. Trends Pharmacol Sci 40(10):790–800

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Geiger R, Rieckmann JC, Wolf T et al (2016) L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167(3):829–42.e13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Giffen KP, Li Y, Liu H et al (2022) Mutation of SLC7A14 causes auditory neuropathy and retinitis pigmentosa mediated by lysosomal dysfunction. Sci Adv 8(14):eabk0942

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gong W, Chen Y, Zhang Y (2021) Prognostic and clinical significance of Solute Carrier Family 7 Member 1 in ovarian cancer. Transl Cancer Res 10(2):602–612

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • He X, Lin H, Yuan L et al (2017) Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice. Cancer Biol Ther 18(2):94–100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • He W, Zhang J, Liu B et al (2020) S119N mutation of the E3 ubiquitin ligase SPOP suppresses SLC7A1 degradation to regulate hepatoblastoma progression. Mol Ther Oncolytics 19:149–162

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heys SD, Segar A, Payne S et al (1997) Dietary supplementation with L-arginine: modulation of tumour-infiltrating lymphocytes in patients with colorectal cancer. Br J Surg 84(2):238–241

    CAS  PubMed  Google Scholar 

  • Heys SD, Ogston K, Miller I et al (1998) Potentiation of the response to chemotherapy in patients with breast cancer by dietary supplementation with L-arginine: results of a randomised controlled trial. Int J Oncol 12(1):221–225

    CAS  PubMed  Google Scholar 

  • Hosokawa H, Sawamura T, Kobayashi S et al (1997) Cloning and characterization of a brain-specific cationic amino acid transporter. J Biol Chem 272(13):8717–8722

    Article  CAS  PubMed  Google Scholar 

  • Huang Y (2007) Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 26(1):183–201

    Article  CAS  PubMed  Google Scholar 

  • Huang Y, Anderle P, Bussey KJ et al (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64(12):4294–4301

    Article  CAS  PubMed  Google Scholar 

  • Huang H, Zhou P, Wei J et al (2021) In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8(+) T cell fate decisions. Cell 184(5):1245–61.e21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ito K, Groudine M (1997) A new member of the cationic amino acid transporter family is preferentially expressed in adult mouse brain. J Biol Chem 272(42):26780–26786

    Article  CAS  PubMed  Google Scholar 

  • Januchowski R, Zawierucha P, Andrzejewska M et al (2013) Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed Pharmacother 67(3):240–245

    Article  CAS  PubMed  Google Scholar 

  • Ji JX, Cochrane DR, Tessier-Cloutier B et al (2020) Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase-deficient ovarian cancer, including small-cell carcinoma of the ovary, hypercalcemic type. Clin Cancer Res 26(16):4402–4413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jiang YQ, Wang ZX, Zhong M et al (2021) Investigating mechanisms of response or resistance to immune checkpoint inhibitors by analyzing cell-cell communications in tumors before and after programmed cell death-1 (PD-1) targeted therapy: an integrative analysis using single-cell RNA and bulk-RNA sequencing data. Oncoimmunology 10(1):1908010

    Article  PubMed  PubMed Central  Google Scholar 

  • Jiang S, Zou J, Dong J et al (2023) Lower SLC7A2 expression is associated with enhanced multidrug resistance, less immune infiltrates and worse prognosis of NSCLC. Cell Commun Signal 21(1):9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jin ZB, Huang XF, Lv JN et al (2014) SLC7A14 linked to autosomal recessive retinitis pigmentosa. Nat Commun 5:3517

    Article  PubMed  Google Scholar 

  • Kelly MP, Jungbluth AA, Wu BW et al (2012) Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer 106(2):324–332

    Article  CAS  PubMed  Google Scholar 

  • Khoury O, Ghazale N, Stone E et al (2015) Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells. J Neurooncol 122(1):75–85

    Article  CAS  PubMed  Google Scholar 

  • Kishikawa T, Otsuka M, Tan PS et al (2015) Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. Oncotarget 6(10):8339–8352

    Article  PubMed  PubMed Central  Google Scholar 

  • Kwong-Lam F, Chi-Fung CG (2013) Vincristine could partly suppress stromal support to T-ALL blasts during pegylated arginase I treatment. Exp Hematol Oncol 2(1):11

    Article  PubMed  PubMed Central  Google Scholar 

  • Lam TL, Wong GK, Chong HC et al (2009) Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett 277(1):91–100

    Article  CAS  PubMed  Google Scholar 

  • Lemos H, Huang L, Prendergast GC et al (2019) Immune control by amino acid catabolism during tumorigenesis and therapy. Nat Rev Cancer 19(3):162–175

    Article  CAS  PubMed  Google Scholar 

  • Lorentzen CL, Martinenaite E, Kjeldsen JW et al (2022) Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - a phase I trial. Front Immunol 13:1023023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lowman XH, Hanse EA, Yang Y et al (2019) p53 promotes cancer cell adaptation to glutamine deprivation by upregulating Slc7a3 to increase arginine uptake. Cell Rep 26(11):3051–60.e4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lukey MJ, Katt WP, Cerione RA (2017) Targeting amino acid metabolism for cancer therapy. Drug Discov Today 22(5):796–804

    Article  CAS  PubMed  Google Scholar 

  • Mccord N, Ayuk P, Mcmahon M et al (2006) System y+ arginine transport and NO production in peripheral blood mononuclear cells in pregnancy and preeclampsia. Hypertension 47(1):109–115

    Article  CAS  PubMed  Google Scholar 

  • Menjivar RE, Nwosu ZC, Du W et al (2023) Arginase 1 is a key driver of immune suppression in pancreatic cancer. eLife 12

  • Miraki-Moud F, Ghazaly E, Ariza-Mcnaughton L et al (2015) Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Blood 125(26):4060–4068

    Article  CAS  PubMed  Google Scholar 

  • Missiaen R, Anderson NM, Kim LC et al (2022) GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab 34(8):1151–67.e7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mussai F, Egan S, Higginbotham-Jones J et al (2015) Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood 125(15):2386–2396

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nakanishi T (2007) Drug transporters as targets for cancer chemotherapy. Cancer Genomics Proteomics 4(3):241–254

    CAS  PubMed  Google Scholar 

  • Nakaya M, Xiao Y, Zhou X et al (2014) Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 40(5):692–705

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nasreddine G, El-Sibai M, Abi-Habib RJ (2020) Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian Cancer cells is autophagy dependent. Invest New Drugs 38(1):10–19

    Article  CAS  PubMed  Google Scholar 

  • Okita K, Hara Y, Okura H et al (2021) Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene. Cancer Sci 112(2):563–574

    Article  CAS  PubMed  Google Scholar 

  • Patil MD, Bhaumik J, Babykutty S et al (2016) Arginine dependence of tumor cells: targeting a chink in cancer’s armor. Oncogene 35(38):4957–4972

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Payne SH, Loomis WF (2006) Retention and loss of amino acid biosynthetic pathways based on analysis of whole-genome sequences. Eukaryot Cell 5(2):272–276

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Peng JB, Zhuang L, Berger UV et al (2001) CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun 282(3):729–734

    Article  CAS  PubMed  Google Scholar 

  • Rodriguez-Ruiz ME, Buqué A, Hensler M et al (2019) Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. Oncoimmunology 8(11):e1655964

    Article  PubMed  PubMed Central  Google Scholar 

  • Rothenberg ME, Doepker MP, Lewkowich IP et al (2006) Cationic amino acid transporter 2 regulates inflammatory homeostasis in the lung. Proc Natl Acad Sci 103(40):14895–14900

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roy DG, Chen J, Mamane V et al (2020) Methionine metabolism shapes T helper cell responses through regulation of epigenetic reprogramming. Cell Metab 31(2):250–66.e9

    Article  CAS  PubMed  Google Scholar 

  • Shen L, Qian C, Cao H et al (2018) Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma. World J Surg Oncol 16(1):235

    Article  PubMed  PubMed Central  Google Scholar 

  • Siska PJ, Rathmell JC (2015) T cell metabolic fitness in antitumor immunity. Trends Immunol 36(4):257–264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Steggerda SM, Bennett MK, Chen J et al (2017) Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer 5(1):101

    Article  PubMed  PubMed Central  Google Scholar 

  • Sun T, Bi F, Liu Z et al (2020) SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer. Aging 12(13):13281–13296

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Szefel J, Danielak A, Kruszewski WJ (2019) Metabolic pathways of L-arginine and therapeutic consequences in tumors. Adv Med Sci 64(1):104–110

    Article  PubMed  Google Scholar 

  • Szlosarek PW, Grimshaw MJ, Wilbanks GD et al (2007) Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer 121(1):6–11

    Article  CAS  PubMed  Google Scholar 

  • Tang K, Zhang H, Deng J et al (2023) Ammonia detoxification promotes CD8(+) T cell memory development by urea and citrulline cycles. Nat Immunol 24(1):162–173

    Article  CAS  PubMed  Google Scholar 

  • Tanios R, Bekdash A, Kassab E et al (2013) Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leuk Res 37(11):1565–1571

    Article  CAS  PubMed  Google Scholar 

  • Tian X, Shi C, Liu S et al (2023) Methylation related genes are associated with prognosis of patients with head and neck squamous cell carcinoma via altering tumor immune microenvironment. J Dent Sci 18(1):57–64

    Article  PubMed  Google Scholar 

  • Vasquez-Dunddel D, Pan F, Zeng Q et al (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Investig 123(4):1580–1589

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vékony N, Wolf S, Boissel JP et al (2001) Human cationic amino acid transporter hCAT-3 is preferentially expressed in peripheral tissues. Biochemistry 40(41):12387–12394

    Article  PubMed  Google Scholar 

  • Verrey F, Closs EI, Wagner CA et al (2004) CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch 447(5):532–542

    Article  CAS  PubMed  Google Scholar 

  • Werner A, Amann E, Schnitzius V et al (2016) Induced arginine transport via cationic amino acid transporter-1 is necessary for human T-cell proliferation. Eur J Immunol 46(1):92–103

    Article  CAS  PubMed  Google Scholar 

  • Werner A, Pieh D, Echchannaoui H et al (2019) Cationic amino acid transporter-1-mediated arginine uptake is essential for chronic lymphocytic leukemia cell proliferation and viability. Front Oncol 9:1268

    Article  PubMed  PubMed Central  Google Scholar 

  • Wolf S, Janzen A, Vékony N et al (2002) Expression of solute carrier 7A4 (SLC7A4) in the plasma membrane is not sufficient to mediate amino acid transport activity. Biochem J 364(Pt 3):767–775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Woodard MH, Dunn WA, Laine RO et al (1994) Plasma membrane clustering of system y+ (CAT-1) amino acid transporter as detected by immunohistochemistry. Am J Physiol 266(5 Pt 1):E817–E824

    CAS  PubMed  Google Scholar 

  • Xia S, Wu J, Zhou W et al (2021) SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell Death Dis 12(6):570

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yan L, He J, Liao X et al (2022a) A comprehensive analysis of the diagnostic and prognostic value associated with the SLC7A family members in breast cancer. Gland Surg 11(2):389–411

    Article  PubMed  PubMed Central  Google Scholar 

  • Yan Y, Chen C, Li Z et al (2022b) Extracellular arginine is required but the arginine transporter CAT3 (Slc7a3) is dispensable for mouse normal and malignant hematopoiesis. Sci Rep 12(1):21832

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yang R, Wang Z, Li J et al (2021) The identification of the metabolism subtypes of skin cutaneous melanoma associated with the tumor microenvironment and the immunotherapy. Front Cell Dev Biol 9:707677

    Article  PubMed  PubMed Central  Google Scholar 

  • Yau T, Cheng PNM, Chiu J et al (2022) A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients. Invest New Drugs 40(2):314–321

    Article  CAS  PubMed  Google Scholar 

  • Yeramian A, Martin L, Serrat N et al (2006) Arginine transport via cationic amino acid transporter 2 plays a critical regulatory role in classical or alternative activation of macrophages. J Immunol 176(10):5918–5924

    Article  CAS  PubMed  Google Scholar 

  • You S, Zhu X, Yang Y et al (2022) SLC7A1 overexpression is involved in energy metabolism reprogramming to induce tumor progression in epithelial ovarian cancer and is associated with immune-infiltrating cells. J Oncol 2022:5864826

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Thanks all the authors for their contributions to this study, which was partially supported by the 2020 Annual Science and Technology Project of Qingdao West Coast New Area (Grant No. 2020-53).

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China

    Shijing You, Xiahui Han, Yuance Xu & Qin Yao

Authors
  1. Shijing You
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiahui Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuance Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qin Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the writing of this review.

Corresponding author

Correspondence to Qin Yao.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Handling editor: E. Closs.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

You, S., Han, X., Xu, Y. et al. Research progress on the role of cationic amino acid transporter (CAT) family members in malignant tumors and immune microenvironment. Amino Acids 55, 1213–1222 (2023). https://doi.org/10.1007/s00726-023-03313-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00726-023-03313-1

Keywords

Search

Navigation